Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Friday, April 27, 2012

All the JAZZ; Biotech/Pharma Stock alert for Jazz Pharmaceuticals (JAZZ)

New York, NY - April 27, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, specializing in sector research, issues a trading alert for Jazz Pharmaceuticals plc (NasdaqGS: JAZZ). The stock is trading at $52.69, up $ 7.49(16.58%)as of 1:54PM EDT on over 3 Million shares.
Yesterday Jazz Pharmaceuticals reported it has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom, for $650 million in cash and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze(TM) (asparaginase Erwinia chrysanthemi), achieving a specified U.S. net sales target in 2013.
Investorideas.com Newswire Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, pain, psychiatry and women's health. The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).
Research biotech stocks at Investorideas.com with the global stock directory of biotech and pharma stocks on the TSX, OTC, NASDAQ, NYSE and other leading exchanges http://www.investorideas.com/ BIS/Stock_List.asp

Get Free investor news and stock alerts at Investorideas.com
Sign Up: http://www.investorideas.com/Resources/ Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks Join: http://www.investorideas.com/ membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech,   China  stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
From time to time Investorideas.com buys shares in companies it features. As a policy, Investorideas.com does not short stocks
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Thursday, April 26, 2012

Medical Technology Stock Alert; A New Audio Interview with Mary Ellen Harrison, VP of Health ID at PositiveID Corporation (OTCBB:PSID), is now at SmallCapVoice.com

AUSTIN, Texas - April 26, 2012 (Investorideas.com newswire) SmallCapVoice.com, Inc. announced today that a new audio interview with PositiveID Corporation (OTCBB:PSID), a developer of medical technologies for diabetes management, is now available. The interview can be heard here.

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit here.
Statements about PositiveID's future expectations, including statements about its iglucose System and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize iglucose; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 29, 2012, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Contact for SmallCapVoice.com:
Stuart T. Smith
512-267-2430
info@smallcapvoice.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and  company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Wednesday, April 25, 2012

Medical Technology Stock Alert; PositiveID (OTCBB:PSID) Named Finalist in 2012 CTIA E-Tech Awards

DELRAY BEACH, Fla. - April 25, 2012 (Investorideas.com newswire) - PositiveID Corporation's (OTCBB:PSID) iglucose was named a finalist in the Healthcare and Wellness Category of CTIA's annual Emerging Technology (E-Tech) Awards competition. The CTIA E-Tech Awards honor the most innovative new products in 15 categories spanning the areas of mobile apps, consumer electronics, enterprise and infrastructure. Winners, including Best in Show and Best Online Pick, will be announced on Wednesday, May 9 at 2:00 p.m. CDT by Jon Fortt, technology correspondent for CNBC on the Exhibit Innovations Stage at International CTIA WIRELESS, taking place May 8--10, 2012 at the Ernest N. Morial Convention Center in New Orleans.
Hundreds of entries were judged by a panel of recognized industry experts, media and analysts and scored on innovation, functionality, technological importance, implementation and overall "wow" factor.
"We are honored iglucose was chosen as a finalist among entries from much larger companies including Alcatel-Lucent, AT&T, HTC, Motorola, Nokia Siemens, Samsung, Qualcomm and others," stated Mary Ellen Harrison, Vice President of Health ID at PositiveID.
Simplicity sets iglucose apart from other mobile health solutions. iglucose can be used by consumers of any technical skill level. It is easy to use and conveniently fits within a pocket or purse. Usability tests conducted as part of the iglucose FDA review process demonstrated 100 percent of consumers were able to use the device regardless of their age. After initial enrollment there are no technology requirements for the end user. Consumers simply connect their glucometer to iglucose and push a button. The iglucose system creates a variety of reports and communicates according to each individual's preferences via online access, email, fax or SMS text.
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. Family members have greater peace of mind; now parents of children with diabetes can receive text messages to let them know their children are testing while at school. iglucose does not require the use of a cell phone or a wireless plan.
Between now and May 8, website visitors may vote for the "Best Online Pick" at www.ctiashow.com/awards. International CTIA WIRELESS show attendees will vote onsite via text message for entries in the E-Tech Awards showcase in Booth 4575 at the Emerging Technology Zone to win "Best in Show."
To vote for iglucose visit http://ctiait.ctia.org/etech/2012/public/index.cfm/viewEntry/617. To learn more about iglucose visit www.iglucose.com or email info@iglucose.com.
For more information on the E-Tech Awards, visit www.ctiashows.com/awards.
For additional details and a comprehensive look at the CTIA conference program, visit: www.ctiawireless.com. Members of the media may pre-register for full access to all show events at: www.ctiashows.com/pressreg.
Follow CTIA Shows:
Facebook: www.ctiashows.com/facebook
LinkedIn: www.ctiashows.com/linkedin
Twitter: www.ctiashows.com/twitter (#CTIAW12)
About CTIA Shows
CTIA Shows bring together all industries advanced by wireless technology for intense business, learning and networking. International CTIA WIRELESS(R) takes place May 8-10, 2012 at the Ernest N. Morial Convention Center in New Orleans, La. CTIA ENTERPRISE & APPLICATIONS(TM) takes place Oct. 9-11, 2012 at the San Diego Convention Center in San Diego, Calif. Visit www.ctiashows.com.
About CTIA
CTIA--The Wireless Association(R) (www.ctia.org) is an international organization representing the wireless communications industry. Membership in the association includes wireless carriers and their suppliers, as well as providers and manufacturers of wireless data services and products. CTIA advocates on behalf of its members at all levels of government. The association also coordinates the industry's voluntary best practices and initiatives, and sponsors the industry's leading wireless tradeshows. CTIA was founded in 1984 and is based in Washington, D.C.
The CTIA Wireless Association logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12582
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and  company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Monday, April 23, 2012

China Stock Trading Alert: Biostar Pharmaceuticals (NASDAQ:BSPM) up over 18% on News

New York, NY, April 23, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, specializing in sector research issues an investor trading alert for  Biostar Pharmaceuticals, Inc. (NasdaqGM: BSPM), trading at $1.9596, up 0.3096(18.76%) as of 2:44PM EDT on over 390,000 shares . The stock has a high of $2.10 on the day .

The Company announced that its Shaanxi Weinan subsidiary, acquired in October 2011, won a bid and has been selected as the exclusive supplier of Huangyangning Tablets, a prescription drug used for the treatment of cardiovascular disease, to all hospitals based in the provinces of Liaoning, Hebei and Shandong for up to three years.  Biostar will supply Huangyangning Tablets to these hospitals based on patient needs in each hospital.

The Company had just announced on April 20th that it had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing of its common stock on The NASDAQ Global Market.


Your browser may not support display of this image.

About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com.

Research China stocks; global China stocks directory at Investorideas.com
 

Get Free investor news and stock alerts at Investorideas.com

Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks Join: http://www.investorideas.com/membership/

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
From time to time Investorideas.com buys shares in companies it features. As a policy, Investorideas.com does not short stocks
            800-665-0411       - Source – www.Investorideas.com

Thursday, April 19, 2012

Medical Technology Stock Alert; PositiveID Corporation's (OTCBB:PSID) iglucose Mobile Health Solution for Diabetes Management to be Featured at CTIA Wireless Emerging Technology Awards Showcase

DELRAY BEACH, Fla. - April 19, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced its FDA-cleared iglucose(R) mobile health system for diabetes management will be featured at the CTIA Emerging Technology (E-Tech) Awards Showcase at the International CTIA Wireless 2012 show from May 8-10, 2012 at the Ernest N. Morial Convention Center in New Orleans, LA. iglucose will be showcased within the category entitled Enterprise & Vertical Market Solution: Healthcare & Wellness.
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals. This makes it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. Family members have greater peace of mind; now parents of children with diabetes can receive text messages to let them know their children are testing while at school. iglucose does not require the use of a cell phone or a wireless plan.
iglucose was designed with the needs of healthcare professionals and people with diabetes in mind. It is simple to use and conveniently fits within a pocket or purse. Usability tests conducted as part of the iglucose FDA review process demonstrated 100 percent of consumers were able to use the device regardless of their age. After initial enrollment there are no technology requirements for the end user. Users simply connect their glucometer to iglucose and push a button. The iglucose system creates a variety of reports and communicates according to the user's preferences via online access, email, fax or SMS text.
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
The International CTIA Wireless show draws more than 40,000 qualified attendees every year, occupies more than 300,000 sq. ft. of exhibit space, hosts over 1,000 exhibitors, attracts more than 1,100 press and analysts worldwide, and offers top-level speakers and the most comprehensive educational programming in the industry. CTIA--The Wireless Association(R) (www.ctia.org) is an international organization representing the wireless communications industry.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and  company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Monday, April 16, 2012

Technology Incubator Los Angeles Syndicate of Technology (OTCQB: LAST) Reports Biotech Portfolio Company Receives IRB Approval

Santa Monica, CA - April 16, 2012 (Investorideas.com Newswire) Los Angeles Syndicate of Technology, Inc. (OTCQB: LAST), a publicly-traded venture fund and technology incubator, is pleased to announce that its portfolio company, Sanguine BioSciences, Inc. ("Sanguine"), has received approval from the Institutional Review Board ("IRB") to collect Biospecimen and Clinical Data from Patients diagnosed with Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease.

The approval by the IRB increases Sanguine's addressable customer markets by allowing Sanguine to collect blood, cerebral spinal fluid, and medical records from a broader base of potential patients. The IRB is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans.

Brian Neman, Founder and Chief Executive Officer, commented: "This marks Sanguine's most significant milestone to date. Not only does it enable us to serve many more research organizations and further the field of drug and biomarker research, but it will also significantly increase our capacity to empower those patients suffering from neurodegenerative and neurological disorders. We founded Sanguine with the vision of empowering patients and accelerating Personalized Medicine research and development, and this milestone is an important step to achieving that vision."

Sanguine currently serves over 60 customers through its global network of ten distributors in nine countries including customers like Harvard Medical School, Vanderbilt University, USC, UCLA, Lonza Group, Seracare, and Cambridge Bioscience. The company has surpassed $100,000 of revenue from USA, Canada, UK, France, Spain, Germany, Italy, Singapore, Japan, Korea, UK, Russia and Israel, with a current pipeline of over 160 purchase orders.

About Los Angeles Syndicate of Technology - www.last.vc

Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.

About Sanguine Biosciences, Inc. - sanguinebio.com

Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.

Forward-Looking Statements

Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.

Contact Information

Contact:

Los Angeles Syndicate of Technology, Inc.
Bryce Knight
(310) 694-0640
www.last.vc

Sanguine Biosciences accelerates Personalized Medicine discovery by providing biological and clinical data, including biospecimen and medical records to researchers, through a direct-to-patient platform that empowers patients in drug and biomarker research. Thousands of patients' biospecimen and medical information are needed to develop new drug and diagnostic, and the company's proprietary model enables it to collect, and ultimately provide patient biospecimen and clinical data much more quickly and less costly than current market standards.

$100,000 in Revenue to Date
$55,000 in Revenue in 2012
60 Customers including
10 distributiors selling to USA, Canada, UK France, Spain, Germany, Italy, Singapore, Japan, Korea, UK, Russia, Israel
161 open purchase orders
The market size for patient and non-patient donor-derived biospecimens is estimated to be >$1B and estimated to grow to >$2.5B by 2015.

About Institutional Review Board

An institutional review board (IRB), also known as an independent ethics committee (IEC) or ethical review board (ERB), is a committee that has been formally designated to approve, monitor, and review biomedical and behavioral research involving humans. In the United States, the Food and Drug Administration (FDA) and Department of Health and Human Services (specifically Office for Human Research Protections) regulations have empowered IRBs to approve, require modifications in planned research prior to approval, or disapprove research. IRBs are responsible for critical oversight functions for research conducted on human subjects that are scientific, ethical, and regulatory.

Disclaimer: Invesorideas.com sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.

Disclosure: Invesorideas.com was compensated by LAST: OB for previous news release and content distribution unrelated to this release. Investorideas.com was not compensated for this news release distribution

www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Stock Alert; PositiveID Corporation's (OTCBB:PSID) iglucose Mobile Health Solution Makes Significant Progress With Active Customer Deployments

DELRAY BEACH, Fla. - April 16, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced significant progress with the initial deployment of its FDA-cleared iglucose(TM) mobile health system for diabetes management. The iglucose System is currently being trialed by a leading health insurer, a large consumer healthcare products company and an international telecommunications provider. The Company also recently announced the use of iglucose in a trial with a leading global pharmaceutical company.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

PositiveID's FDA-cleared iglucose System is a convenient and easy-to-use wireless solution designed to empower individuals with diabetes to become more engaged in the self-management of their condition. iglucose seamlessly communicates blood glucose data from glucometers to the iglucose diabetes management portal, where reports are generated and can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and enables individuals with diabetes to proactively take control of their glucose levels and treatment regimens. iglucose does not require the use of a cell phone or a wireless plan.

"Many large organizations are currently trialing iglucose, from one of the largest health insurers in the U.S., to one of the largest consumer healthcare products companies in the world," stated William J. Caragol, PositiveID's Chairman and CEO. "We are providing this progress report following our announcement last week that we made iglucose available for pre-order for consumers. We received a very positive response and therefore want to update the investor community as well as those with diabetes about our next steps."

The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.

About PositiveID Corporation OTCBB:PSID)

PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT:

Allison Tomek
561-805-8000
atomek@positiveidcorp.com

Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Pacific Therapeutics Ltd. (PT.CNSX) PROGRESS OF CLINICAL DEVELOPMENT

PROGRESS OF CLINICAL DEVELOPMENT VANCOUVER, BRITISH COLUMBIA – April 16, 2012 (Investorideas.com Newswire) Pacific Therapeutics Ltd. (PT.CNSX) (the “Company”) is pleased to provide an update on the progress of the clinical development of PTL-202. As previously announced the Company has engaged CRBIO of India to conduct a drug drug interaction study of PTL-202 and its components. CRBio has submitted the PTL-202 drug-drug interaction clinical trial protocol to the Central Drugs Standard Control Organization Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India.

The clinical study protocol is currently being reviewed by the Central Drugs Standard Control Organization ( India 's pharmaceutical regulatory authority). The study will be conducted once this regulatory approval is received, which is expected this quarter. The study protocol calls for dosing of 12 normal healthy adult males. This an open label, non randomized, three treatment, three period single dose study. Once enrolment is completed the study should only take 1 month to complete.

The lack of any drug drug interaction will be a positive result and signal the continued clinical development of PTL-202. CRBio is 'full service' contract research organization. It is set up in a centrally located area in Hyderabad India . The facility is spread over 20,000 sq.ft. in well laid out areas with operations such as Clinical, Bioanalytical, Pharmacokinetic & Statistical, QA & RA , QC . With 4 full time doctors plus paramedical staff, clinics consist of 72 beds and CRBio has a 3,000 volunteer database and a state of the art bioanalytical laboratory. CRBio as an independent contractor has completed over 150 BA/BE (Bioavailability Bioequivalence) projects similar to the PTL-202 drug drug interaction study.

ABOUT PACIFIC THERAPEUTICS LTD. (http://www.pacifictherapeutics.com/)

Pacific Therapeutics Ltd is a clinical stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis). The company's lead drug candidate PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating intermittent claudication) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. PTL-202 is currently being reviewed for initial trials in humans which are expected to commence in 2012. PTL-202 a combination of approved drugs focused on treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.

The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.

FORWARD LOOKING STATEMENTS Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events.

This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

On Behalf of the Board of Directors /s/ Doug Unwin Douglas H. Unwin, CEO & President

(604) 738-1049

unwin@pacifictherapeutics.com www.pacifictherapeutics.com

Friday, April 13, 2012

Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Offers iglucose Mobile Health Solution to Rural Healthcare Providers

DELRAY BEACH, Fla. - April 13, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it is offering its FDA-cleared iglucose(R) mobile health system for diabetes management to rural healthcare providers, who care for approximately 62 million people in the U.S. To promote its awareness among rural healthcare providers, iglucose will be demonstrated at the National Rural Health Association's 35th Annual Rural Health Conference from April 17-20, 2012, at the Hyatt Regency Denver, Colorado Convention Center, in conjunction with healthcare solutions provider Merge-MD in booth #213.

PositiveID's FDA-cleared iglucose System uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. The iglucose system creates a variety of reports and communicates according to the user's preferences via online access, email, fax or SMS text. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.

"The response to iglucose from our customers and prospects is overwhelming. iglucose is a perfect rural tele-health solution for people with diabetes and those who care for them," stated Scott Griffith, Chief Operating Officer of Merge-MD. "Most people with diabetes need to be seen every 90 days, which can be a challenge when many endocrinologists and diabetes educators are located in major cities, not small towns. With iglucose, information can be shared at any time with healthcare professionals who are hundreds of miles away."

The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. PositiveID is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.

The National Rural Health Association's 35th Annual Rural Health Conference nation's largest rural health conference, created for all of those with an interest in rural health care, including rural health practitioners, hospital administrators, clinic directors and lay health workers, social workers, state and federal health employees, academics, community members, and all others interested in rural health care.

About Merge-MD

Merge-MD is an innovative healthcare solutions company founded and focused on how health information technology (including electronic health and medical records), processes and people can work together to advance the quality of healthcare. Merge-MD believes electronic health records should follow patients in real time so healthcare providers can make fast, safe decisions, reduce costs by eliminating redundant care and improve the quality of care overall.

About PositiveID Corporation OTCBB:PSID)

PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT:

Allison Tomek
561-805-8000
atomek@positiveidcorp.com

Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Thursday, April 12, 2012

Healthcare investors and Biotech Traders Podcast: Company Spotlight on Sirona Biochem (TSX-V: SBM, OTC: SRBCF)

New York, New York � April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks releases an investor podcast for biotech traders and investors with a company spotlight on a small biotech company making headway in the diabetes and obesity market with its core technology.

Sirona Biochem Corp (TSX-V: SBM , OTC: SRBCF), is a company using Carbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.

Listen to Podcast

Podcast link

About Sirona Biochem Corp (www.sironabiochem.com)

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com

Biotech Company Develops Promising Potential Treatment for Type 2 Diabetes and Obesity

New York, New York - April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech company snapshot for Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), a company using arbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

Sodium Glucose Transporter (SGLT) Inhibitors - Diabetes & Obesity

Sirona Biochem is developing SGLT inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas and affect metabolism. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.

The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood by SGLT transporters. SGLT inhibitors reduce the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they can help regulate glycemia. This is a new promising potential treatment for Type 2 diabetes and obesity.

Status & Milestones

Preclinical animal tests of Sirona Biochem's SGLT inhibitor for Type 2 diabetes are well underway with the positive results posted in the first quarter of 2011. Additional preclinical studies to test the safety and toxicology of this SGLT inhibitor are currently being conducted. Sirona Biochem plans to independently complete preclinical studies to prepare its SGLT inhibitor for human clinical trials. A pharmaceutical partner will be sought for clinical and commercial development of our program.

Watch the video on SBM's technology - how it works:

http://www.youtube.com/watch?feature=player_embedded&v=F_fAzxsf7hk

About Sirona Biochem Corp (www.sironabiochem.com)

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member

http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

Disclosure - Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com

Wednesday, April 11, 2012

Biotech Stock to Watch: Sirona Biochem (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB)

New York, New York - April 11, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech investor spotlight for Sirona Biochem Corp . (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB).

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

Investor video on SBM's technology!

Read the previous news release. SBM just closed a private placement of over $1 Million dollars!

http://www.sironabiochem.com/sirona-closes-non-brokered-private-placement-of-1406500/

Today's News:

Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochems scientific poster has been selected to be on display during the Difficult to Express Proteins track April 30 to May 1, 2012.

The Eighth Annual PEGS conference, to be held April 30 May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.

Sirona Biochems scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.

Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.

A copy of the poster will be made available on the companys website at www.sironabiochem.com after the conference.

About Sirona Biochem Corpwww.sironabiochem.com

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member

http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com

Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Begins Orders of iglucose at www.iglucose.com

DELRAY BEACH, Fla. - April 11, 2012 (Investorideas.com newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced it has begun taking orders of its FDA-cleared iglucose(R) mobile health system for diabetes management. Pre-orders are being accepted through the iglucose website at www.iglucose.com and the PositiveID website at www.positiveidcorp.com. PositiveID expects to commercially launch iglucose during the second quarter of 2012.

PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.

"As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management," stated William J. Caragol, Chairman and CEO of PositiveID. "Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers."

The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.

About PositiveID Corporation OTCBB:PSID)

PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT:

Allison Tomek
561-805-8000
atomek@positiveidcorp.com

Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Investor Alert: Sirona Biochem (TSX-V: SBM) to Present Scientific Poster of Inducer Program at 2012 Protein Engineering Summit (PEGS)

Vancouver, British Columbia - April 11, 2012 (InvestorIdeas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochem's scientific poster has been selected to be on display during the “Difficult to Express Proteins” track April 30 to May 1, 2012.

The Eighth Annual PEGS conference, to be held April 30 - May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.

Sirona Biochem's scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.

Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.

A copy of the poster will be made available on the company's website at www.sironabiochem.com after the conference.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Published at the Investorideas.com Newswire

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers

Tuesday, April 10, 2012

LAST (OTCQB: LAST) Announces Incubator Portfolio of Social Networking and Biotech Companies

SANTA MONICA, CA - April 10, 2012 (Investorideas.com Newswire) - Los Angeles Syndicate of Technology, Inc. (OTCQB: LAST.OB), a Business Development Company (BDC) that incubates early stage technology companies, has announced the successful launches of the first three portfolio companies built within its technology incubator. LAST is the largest shareholder of each of the three companies including Sanguine Biosciences, a bio-specimen supplier; Virurl, Inc., a social advertising platform; and Stocktown Productions, a digital production studio.
Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

"We are encouraged that our first three portfolio companies are generating revenue and expanding operations," said Bryce Knight, CEO of LAST. He added "We are excited to bring new team members into the LAST network to support the growth of these companies and to continue developing our second class of companies under the LAST umbrella."

About Los Angeles Syndicate of Technology - www.last.vc

Los Angeles Syndicate of Technology, Inc. (OTC: LAST.OB) is a publicly traded Business Development Company (BDC) that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, consumer internet, and social networking products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, support and tools to bring their ideas to market and commercialize their products.

About Sanguine Biosciences, Inc. - sanguinebio.com

Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines. Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.

About Virurl, Inc. - virurl.com

Virurl, Inc. ("Virurl") is an online advertising platform that allows advertisers to incentivize people to share links with their friends. By creating a forum where users are rewarded for sharing links, the VIRURL platform empowers content creators and advertisers to tap the organic social networks of the web to drive traffic to their sites. Virurl is a "human-powered" advertising engine, enabling users to earn cash and rewards for what they are already doing everyday - sharing links with their friends.

About Stocktown Productions, Inc. - stocktownproductions.com

Stocktown Productions, Inc. ("Stocktown") is a digital production studio based in Santa Monica, California, specializing in video, animation and 3-D visual effects. In addition to video production, Stocktown provides innovative web and graphic design - bringing an original style and cutting-edge concepts to each project.

Forward-Looking Statements

Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.

Contact Information

Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
310) 694-0640
www.last.vc

Published at Investorideas.com Newswire

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of company news .

www.InvestorIdeas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894